What do you get if you combine MIT with a Nobel Peace Prize winner and a determined individual? The answer is simple. You get Scott Rocklage, PhD. When attending MIT, Scott was led by Professor Richard Schrock. Dr. Rocklage earned his doctorate in chemistry. Learn more about Scott Rocklage: https://thebrotalk.com/bro-bio/bro-bio-enigmatic-mysterious-life-dr-scott-rocklage/ and https://www.twst.com/bio/scott-m-rocklage/
In 2016, Scott and his wife were invited back to MIT to be honored for a generous donation that they made to help renovate the existing lab.
After being honored at MIT, the couple were taken on a tour of the newly renovated lab department and stopped within the labs vestibule where they were shown a plaque that was hung in their honor. The department head, Timothy Jamison was the one in charge of honoring the couple.
Scott Rocklage is more than just an graduate from MIT, he is also a managing partner for 5AM Ventures. He came in as an Venture partner and was quickly upgraded to a managing partner just a year after joining.
He carries with him more than 3 decades of knowledge of the healthcare management field and helped to push three new drugs through the approval process with the FDA. Scott Rocklage graduated from the University of California with his bachelors degree in chemistry and then went on to MIT to study under Richard Schrock. Read more: Scott Rocklage | Ideamesch and Scott Rocklage | Crunchbase
With former experience with board chairs and serving now on the chairman board for Rennovia, Kinestral and Cidara. His reach goes so much further with the board of Epirus and Pulmatrix. Scott talks about his days being far from typical days in business.
When going over what he spends his days on, Scott talks about some days working on new areas of expertise in life science as well as working with management teams and heading to board meetings on a number of the boards he serves as chairman of.
When Scott was interviewed and asked about the one trend that he is most excited to work with and see change in, he talks about working with specific mutations as well as genotypes to help come up with a way to treat cancer. They have already helped many patients with techniques and treatments to help extend their lives.